TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
11.95
+0.10 (0.84%)
Feb 18, 2025, 9:00 AM CST
-23.15%
Market Cap 8.29B
Revenue (ttm) 148.75M
Net Income (ttm) 171.74M
Shares Out 717.84M
EPS (ttm) 0.24
PE Ratio 48.40
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,000
Average Volume 1,088,013
Open 11.90
Previous Close 11.85
Day's Range 11.90 - 12.00
52-Week Range 10.60 - 17.25
Beta 0.92
RSI 51.08
Earnings Date Mar 21, 2025

About TPEX:4157

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4157
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.